Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 5/20 | 0.60 |
| ▸ | AXL | P30530 | 4/20 | 0.54 |
| ▸ | HTR6 | P50406 | 10/20 | 0.49 |
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR1D | P28221 | 2/20 | 0.47 |
| ▸ | HTR1B | P28222 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5417051 | 0.99 | ITK (0.59) | ITKAXLHTR6ULK1HTR1A | |
| SCHEMBL3555398 | 0.76 | HTR6 (0.72) | ITKHTR6HTR1AHTR1DHTR1B | |
| SCHEMBL5413599 | 0.76 | ITK (0.67) | ITK | |
| SCHEMBL22253262 | 0.76 | DYRK1A (0.72) | — | |
| SCHEMBL3552557 | 0.75 | HTR6 (0.69) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| Hydrochloric Acid SCHEMBL5408142 | 0.75 | ITK (0.66) | ITK | |
| SCHEMBL5412544 | 0.75 | ITK (0.55) | ITKAXL | |
| Hydrochloric Acid SCHEMBL3625883 | 0.74 | HTR6 (0.48) | ITKAXLHTR6HTR1AHTR1D | |
| SCHEMBL3549315 | 0.74 | HTR6 (0.72) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL16847274 | 0.74 | MAPK1 (0.44) | ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ITK 1422/4885AXL 1805/4885HTR6 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.